FP14.11 Icotinib versus Chemotherapy as Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study
Caicun Zhou(Tongji University), Li Mao(Washington State University), C. Chen(Fujian Medical University), Bing Hu(Sichuan University), F. Ye(First Affiliated Hospital of Xiamen University), Yimeng Liu(Chinese PLA General Hospital), Wenhua Liang(First Affiliated Hospital of Guangzhou Medical University), Taiqian Gong(Chinese PLA General Hospital), X. Li, C. Su(Tongji University), Xinyi Zhang(Wenzhou Medical University), Shidong Xu(Harbin Medical University), Z. Xiao(The First People's Hospital of Changde), X. Liu(Chinese PLA General Hospital), Jiahao Hu(Harbin Medical University), Lin Wu(Materials Systems (United States)), Jing Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Xu(Guangdong Pharmaceutical University), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Rui‐Hua Xu(Sun Yat-sen University), Yunchao Huang(North China University of Water Resources and Electric Power), Haitao Ma(Yunnan University), Z. Liu(Capital Medical University), Guoguang Shao(Jilin University), Lijiang Ding(Shaoxing People's Hospital), Di Ge(Fudan University), Jingpeng Fu(Harbin Medical University), Xinlei Fu(Tongji Hospital), W. Li(Jilin University), Weimin Mao(Bristol-Myers Squibb (Germany)), Zengming Wang(Second Military Medical University)
Cited by 5
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial
|Journal of Clinical Oncology|2018|976
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868